The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / HCQ Prolongs QT Interval in Patients with COVID-19

HCQ Prolongs QT Interval in Patients with COVID-19

May 5, 2020 • By Will Boggs, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Potentially dangerous prolongation of the QT interval is common among patients hospitalized with COVID-19 who receive hydroxychloroquine (HCQ) with or without concomitant azithromycin, according to two new studies.

You Might Also Like
  • U.K. Healthcare Workers Begin COVID-19 HCQ Trial
  • Hydroxychloroquine Tied to Increased Risk of Death in COVID-19 Patients
  • Hydroxychloroquine Combination Risky for Cancer Patients with COVID-19

“This is a well-known problem with HCQ and azithromycin, which became amplified in this higher risk population,” Christina F. Yen, MD, from Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, told Reuters Health by email.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In the first study, Dr. Yen and colleagues sought to characterize the risk and degree of QT prolongation in 90 patients with COVID-19 in association with their use of HCQ with or without concomitant azithromycin.

One-third of these patients were critically ill at the time of testing, and 26% were mechanically ventilated. All patients received HCQ, and 59% also received azithromycin. Most patients had at least one cardiovascular mortality and were taking two or more QTc-prolonging medications.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Median corrected QT interval (QTc) was 455 ms at baseline. With treatment the QTc increased by 60 ms or more in 10 patients (11%) and 18 patients (20%) had posttreatment QTc of 500 ms or more.

The number of patients who developed prolonged QTc of 500 ms or more was greater with concomitant azithromycin (11/53, 21%) than with HCQ monotherapy (7/37, 19%), as was the percentage of patients whose QTc increased by 60 ms or more (13% versus 3%, respectively), according to the online report in JAMA Cardiology.1

Concomitant loop diuretic administration and a baseline QTc of 450 ms or more were independently associated with an increased likelihood of prolonged QTc.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Adverse events possibly related to HCQ treatment included intractable nausea, development of new premature ventricular contractions and right bundle branch block, and hypoglycemia.

One patient whose hydroxychloroquine and azithromycin were discontinued because of QTc prolongation (499 ms) developed torsades de pointes three days later and subsequently developed other ventricular arrhythmias that required lidocaine treatment.

“This highlights hydroxychloroquine’s long half-life, allowing QTc prolonging effects to linger even after discontinuation,” Dr. Yen says.

“This study underscores that use of HCQ and azithromycin in hospitalized COVID-19 patients must be done cautiously and ideally in the setting of a clinical trial, as recommended by multiple international guidelines,” she says. “We hope that those seeking to use HCQ, with or without azithromycin, consider our study and other peer-reviewed data regarding the safety and efficacy of these drugs for the treatment of COVID-19. It is not clear that our current understanding of the risk/benefit of HCQ favors its use for COVID-19.”

Pages: 1 2 3 | Single Page

Filed Under: Drug Updates Tagged With: coronavirus, COVID-19, Hydroxychloroquine (HCQ)

You Might Also Like:
  • U.K. Healthcare Workers Begin COVID-19 HCQ Trial
  • Hydroxychloroquine Tied to Increased Risk of Death in COVID-19 Patients
  • Hydroxychloroquine Combination Risky for Cancer Patients with COVID-19
  • WHO Expects HCQ Safety Findings by Mid-June

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)